The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology
Revision 7

ENCePP Guide, Revision 7 - Authorship

Editors
Alexandra Pacurariu, Xavier Kurz and the ENCePP Working Group Research Standards and Guidances

Design and layout
Dagmar Vogl

Main authors

1. Introduction: Xavier Kurz
2. Formulating the research question: Yola Moride, Massoud Toussi
3. Development of the study protocol: Annie Fourrier-Réglat
4. Approaches to data collection
   4.1. Primary data collection: Susana Perez-Gutthann
       4.1.1. Surveys: Massoud Toussi
       4.1.2. Randomised clinical trials: Susana Perez-Gutthann
   4.2. Secondary data collection: Susana Perez-Gutthann, Gianluca Trifirò
4.3. Patient registries: Xavier Kurz

4.4. Spontaneous reports: Niklas Norèn, Jim Slattery

4.5. Social media: Victoria Newbould, Niklas Noren, Annie Fourrier-Réglat, Massoud Toussi

4.6. Research networks: Miriam Sturkenboom

5. Study design and methods

5.1. Definition and validation of drug exposure, outcomes and covariates: Alejandro Arana, Gillian Hall, Jesper Hallas, Rachael Williams

5.2. Bias (systematic error): Olaf Klungel, Jesper Hallas, Vera Ehrenstein, Mirko Di Martino, Ursula Kirchmayer, Alejandro Arana, Alexandra Pacurariu

5.3. Methods to address bias: Rolf Groenwold, Jesper Hallas, Olaf Klungel, Vera Ehrenstein, Gillian Hall

5.4. Effect measure modification and interaction: Olaf Klungel, Federica Pisa

5.5. Ecological analyses and case-population studies: Ursula Kirchmayer

5.6. Pragmatic trials and large simple trials: Olaf Klungel, Tjeerd van Staa

5.7. Systematic reviews and meta-analysis: Gillian Hall, Nawab Qizilbash, Daniel Morales

5.8. Signal detection methodology and application: Niklas Norèn, Jim Slattery, Gianmario Candore

5.9. Methods for pharmacovigilance impact research: Helga Gardarsdottir, Thomas Goedecke, and the ENCePP Special Interest Group on Measuring the Impact of Pharmacovigilance Activities

6. The statistical analysis plan: Jim Slattery, Alejandro Arana

7. Quality management: Milena Jadrijević-Mladar Takač

8. Dissemination and communication of study results: Kevin Blake, Susana Perez-Gutthann

9. Data protection and ethical aspects

9.1. Patient and data protection: Xavier Kurz, Kevin Blake

9.2. Scientific integrity and ethical conduct: Xavier Kurz, Kevin Blake

10. Specific topics

10.1. Comparative effectiveness research: Annie Fourrier-Réglat, Olaf Klungel, Federica Pisa

10.2. Vaccine safety and effectiveness: Phillip Bryan, Alfonso Carvajal, Xavier Kurz

10.3. Design and analysis of pharmacogenetic studies: Olaf Klungel, Bruno Stricker, Bruce Carleton (in collaboration with the ISPE SIG "Molecular Epidemiology, Biomarkers and Pharmacogenetics")

Annex 1 Nawab Qizilbash, Jim Slattery and Kevin Blake

Annex 2 Helga Gardarsdottir, Thomas Goedecke, Alexandra Pacurariu, Daniel Morales and the ENCePP Special Interest Group on Measuring the Impact of Pharmacovigilance Activities
Acknowledgements

Peer review of one or several chapters was received from:
Amalia Issa
Ana Marta Anes
Ann Daly
Annalisa Rubino
Brian Strom
Camilla Stephens
Consuelo Pedros
David Martin
Elisabetta Poluzzi
Frank DeStefano
Geoff Liu
Gillian Bartlet
Gonzalo Calvo
Gunilla Sjolin-Forsberg
Hervé Le Louet
Hubert Leufkens
Ivana Silva
Jan Bonhoeffer
John Parkinson
Kenneth J. Rothman
Lina Titievski
Marina Davoli
Mark de Groot
Martin Daumer
Michael Theodorakis
Munir Pirmohamed
Nada Božina
Nancy Dreyer
Paddy Farrington
Patrick Zuber
Peter Arlett
Robert Vander Stichele
Samy Suissa
Sarah McFarlane
Sebastian Botzenhardt
Sebastian Schneeweiss
Stefanie Prilla
Stephen Evans
Teresa Herdeiro
Ulf Bergman
Vera Ehrenstein
Viktor Kiri
Wei Zhou
Xavier Fournie
Yvonne Lis